Source link : https://www.newshealth.biz/health-news/belantamab-mafodotin-the-comeback-drug-in-multiple-myeloma/
At the American Society of Clinical Oncology (ASCO) annual meeting, positive findings were presented on two phase III trials — DREAMM-7 and DREAMM-8 — testing belantamab mafodotin (Blenrep) in multiple myeloma. Belantamab mafodotin had received accelerated approval in 2020 but in 2022 was withdrawn from the U.S. market following a failed confirmatory study. MedPage Today […]
Author : News Health
Publish date : 2024-07-05 16:44:54
Copyright for syndicated content belongs to the linked Source.
Categories